The contradiction between correction of anemia and creation of anemia in this study is therefore explained by the fact that we studied two molecules with slightly different modes of action, baricitinib being a more significant inhibitor of JAK2 than tofacitinib. This evidence concerns the gene JAK2 and anemia (phenotype).